Identification of subtypes in HER2-positive breast cancer reveals a gene signature prognostic of outcome

ABSTRACT: Purpose HER2 gene amplification or protein overexpression (HER2+) defines a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. We aimed to investigate the heterogeneous biological appearance and clinical behavior of HER2+ tumors using molecular profiling. Materials and Methods Hierarchical clustering of gene expression data from 58 HER2-amplified tumors of various stage, histological grade and estrogen receptor (ER) status was used to construct a HER2-derived prognostic predictor that was further evaluated in several large independent breast cancer data sets. Results Unsupervised analysis identified three subtypes of HER2+ tumors with mixed stage, histological grade and ER-status. One subtype had a significantly worse clinical outcome. A pro

ORGANISM(S): Homo sapiens

SUBMITTER: Ake Borg 

PROVIDER: E-GEOD-18328 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress